Astrocytes Mount Complex Responses to AD. They Change Over Time
Single-nuclei RNA-Seq of 600,000 astrocytes defined seven subtypes. One revs up metabolic support late in Alzheimer’s disease, before flagging at its end stage.
ALL NEWS
6654 RESULTS
Sort By:
- Most Recent
- Most Commented
Receptors and Broken Lysosomes Explain Risk from APOE Variants
ApoE4 transports toxic lipids into lysosomes. ApoE2 and Christchurch variants do not.
'Presymptomatic AD' or 'Asymptomatic at Risk'? Dx Criteria Disagree
Alzheimer’s Association diagnostic criteria favor the former term, International Working Group the latter, for cognitively healthy people with AD biomarkers.
In Familial Alzheimer’s, β-Synuclein Rises in Blood a Decade Before Onset
In ADAD mutation carriers, blood β-synuclein crept up after their amyloid-PET scans had turned positive, but before axons degenerated. Does it reflect crumbling synapses?
What’s Inside Those Mysterious Biondi Bodies? Hello, TMEM106B!
Cryo-EM identifies a similar protein fold in these ependymal cell inclusions as in parenchymal TMEM106b fibrils.
Just as Sharp: MRI Scans at Triple the Speed
By utilizing advances in parallel imaging, scientists cut the time needed for diagnostic MRI scans from 18 to 6.5 minutes, without a noticeable loss in quality.
Beyond Antibodies: From CTAD, New Attempts at Outflanking Alzheimer’s
Early stage trials hint that new therapeutics could take down APP, boost ApoE2, or fix inflammatory and metabolic dysfunction in AD.
Some Alzheimer’s Blood Tests Are Racing Toward IVD Certification
Vendors of plasma p-tau217-based tests are filing with U.S. and European regulators for approval of fully automated, in vitro diagnostics.
Biomarkers Suggest Black and Hispanic People Less Likely to Have Amyloid
The findings suggest that non-AD pathologies, driven by other comorbidities, might contribute to cognitive decline in these populations.
AI to Spot ARIA? FDA Says Yes
The commercial software icobrain aria sharpened radiologists’ detection of ARIA-E and ARIA-H. The FDA approved the technology for clinical use November 7.
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
In Madrid, researchers touted the benefits of plasma prescreening and showed baseline data on these early AD populations. Meanwhile, remternetug has begun Phase 3.
Tau Modification Drugs Take a Hit with Negative Trial
Lilly’s Phase 2 trial of its O-GlcNAcase inhibitor ceperognastat failed to meet clinical endpoints. The drug’s adverse events suggest potential off-target effects.
Finally, Therapeutic Antibodies Start to Reduce Tangles
Bepranemab results bolster hopes for antibodies targeting tau’s middle section. Whether tangle clearance will improve clinical outcomes remains unclear.
Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial
ARIA rates have been the same or lower than in the Phase 3 trial. About 9,000 people are being treated in the U.S., half as many in Japan. EMA reverses course, recommending approval.
Clinical Trials on Alzheimer's Disease (CTAD) 2024- 17th
Trontinemab Data Strengthen Hope for Brain Shuttles Donanemab: Small Tweak in Titration, Big Gain in Safety? Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial Finally, Therapeutic Antibodies Start to Reduce Tangles Tau Modification Dr
Current Filters
No filters selected